Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
A K Thom, H R Alexander, M P Andrich...
https://pubmed.ncbi.nlm.nih.gov/7799030Completed
Phase 1
All Genders
ID00001577
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
Led by National Cancer Institute (NCI) · Updated on 2008-03-04
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Hyperthermic isolated limb perfusion with melphalan alone is administered as a double perfusion schedule. These two isolates limb perfusions with melphalan are treated 3-6 weeks apart. After perfusion is established, the leak rate has been determined to be acceptable, and tissue temperatures are 38 degrees Celsius, then the melphalan is administered by slow injection into an arterial line over approximately 5 minutes. The perfusion with melphalan will then continue for 60 minutes, after which the extremity is flushed out with a total of 3 liters of fluid consisting initially of a saline solution. The dose of melphalan for the second perfusion will be increased. An attempt to resect the residual lesion between 6-12 weeks after the second interval perfusion may be made.
CONDITIONS
Official Title
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
DISEASE CHARACTERISTICS:
Histologically confirmed unresectable sarcoma or intransit melanoma of the upper or lower extremity.
Extremity sarcoma with no local resection option and would require amputation based upon abutment or proximity of the tumor to major neurovascular structures or bone or joint structures.
MELANOMA PATIENTS:
Must have history of two or more satellite intransit metastases of which one may be excised for diagnosis with the exception of patients with a single, large, deep, locally recurrent tumor or metastatic tumor (greater than 5 cm) that precludes an excision with primary closure. Stage IV melanoma must have a significant component (greater than 90%) of disease distal to the apex of the femoral triangle in the lower limb or distal to the insertion of the deltoid in the upper limb.
Must have evaluable disease in the extremity. Melanoma must have dermal or subcutaneous lesion that can be measure directly in two diameters to assess tumor burden. Sarcoma must have either cutaneous lesions amenable to direct measurement or deeper lesions that can be measured on CT or MRI scans.
PRIOR/CONCURRENT THERAPY:
At least 2 months since any regional therapy to the affected extremity.
BIOLOGIC THERAPY: At least 1 month since Biologic Therapy.
CHEMOTHERAPY: At least 1 month since chemotherapy.
ENDOCRINE THERAPY: Not specified.
RADIOTHERAPY: At least 1 month since radiotherapy.
SURGERY: Not specified.
PATIENT CHARACTERISTICS:
AGE: 18 and over.
PERFORMANCE STATUS: ECOG 0-2.
LIFE EXPECTANCY: At least 6 months.
HEMATOPOIETIC: Platelet count greater than 150,000/mm(3).
HEPATIC: Bilirubin less than 2.0 mg/dL.
RENAL: Creatinine less than 2.0 mg/dL.
CARDIOVASCULAR: No history of congestive heart failure with an LVEF less than 40%.
PULMONARY:
No chronic obstructive pulmonary disease.
No other chronic pulmonary disease with PFTs less than 50% predicted for age.
OTHER:
IF HIV POSITIVE: Must have CD4 cell count greater than 500/mL and, No clinical manifestations of AIDS. Coagulation parameters no greater than 1-2 seconds within the upper limit of normal.
No evidence of severe peripheral vascular disease.
No history of claudication or other ischemic vascular disease.
Not pregnant or nursing.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Isolated limb perfusion for malignant melanoma.
H R Alexander, D L Fraker, D L Bartlett
https://pubmed.ncbi.nlm.nih.gov/8914206